AR114156A1 - MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE - Google Patents
MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTEInfo
- Publication number
- AR114156A1 AR114156A1 ARP180103577A ARP180103577A AR114156A1 AR 114156 A1 AR114156 A1 AR 114156A1 AR P180103577 A ARP180103577 A AR P180103577A AR P180103577 A ARP180103577 A AR P180103577A AR 114156 A1 AR114156 A1 AR 114156A1
- Authority
- AR
- Argentina
- Prior art keywords
- heart failure
- cycloalkyl
- alkoxy
- dialkylamino
- alkylamino
- Prior art date
Links
- 108060003345 Adrenergic Receptor Proteins 0.000 title abstract 3
- 102000017910 Adrenergic receptor Human genes 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 5
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004043 oxo group Chemical group O=* 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010024119 Left ventricular failure Diseases 0.000 abstract 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005275 alkylenearyl group Chemical group 0.000 abstract 1
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000005392 carboxamide group Chemical class NC(=O)* 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004992 haloalkylamino group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- -1 hydroxycarbamimidoyl Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) y a composiciones farmacéuticas de estos que modulan la actividad del receptor adrenérgico b-3. Los compuestos de la presente y las composiciones farmacéuticas de estos se refieren a métodos útiles para el tratamiento de un trastorno mediado por el receptor adrenérgico b-3, como, insuficiencia cardiaca; rendimiento cardíaco en la insuficiencia cardíaca; mortalidad, reinfarto y/u hospitalización relacionada con la insuficiencia cardíaca; insuficiencia cardíaca aguda; insuficiencia cardíaca descompensada aguda; insuficiencia cardíaca congestiva; insuficiencia cardíaca congestiva grave; daño a un órgano asociado con insuficiencia cardíaca; insuficiencia cardíaca debido a disfunción ventricular izquierda; insuficiencia cardíaca con fracción de eyección normal; mortalidad cardiovascular después de un infarto de miocardio; mortalidad cardiovascular en pacientes con insuficiencia ventricular izquierda o disfunción ventricular izquierda; insuficiencia ventricular izquierda; disfunción ventricular izquierda; insuficiencia cardíaca de clase II; insuficiencia cardíaca de clase III; insuficiencia cardíaca de clase IV; LVEF < 40% según ventriculografía por radionúclidos; LVEF & Reivindicación 1: Un compuesto seleccionado de los compuestos de fórmula (1) y sales, solvatos, hidratos y N-óxidos farmacéuticamente aceptables de este, en donde: X es -SO₂- o está ausente; R¹ se selecciona de: arilo, alquileno C₁₋₆-arilo, alquileno C₁₋₆-heteroarilo, cicloalquilo C₃₋₇, heteroarilo y heterociclilo; cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados de: alcoxi C₁₋₆, alcoxicarbonilo C₁₋₆, alquilo C₁₋₇, alquilamino C₁₋₆, alquilcarboxamida C₁₋₆, alquilsulfonamido C₁₋₆, alquilsulfonilo C₁₋₆, amino, ariloxi, arilsulfonilo, carboxamida, carbamimidoil, carboxi, ciano, cicloalquilo C₃₋₇, dialquilamino C₂₋₈, dialquilsulfamoil C₂₋₈, haloalcoxi C₁₋₆, haloalquilo C₁₋₆, halógeno, heterociclilo, hidroxicarbamimidoil, hidroxilo, oxo y sulfamoil; y en donde dicho alcoxi C₁₋₆, alquilo C₁₋₇, alquilamino C₁₋₆, ariloxi, cicloalquilo C₃₋₇ y dialquilamino C₂₋₈ están cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados de: amino, alcoxi C₁₋₆, alquilamino C₁₋₆, alquilcarboxamida C₁₋₆, carboxi, Y-alquileno C₁₋₆-Z opcionalmente sustituido con oxo, cicloalquilo C₃₋₇, ciano, dialquilamino C₂₋₆, haloalquilo C₁₋₆, haloalquilamino C₁₋₆, heterociclilo, hidroxilo, oxo y fenilo; Y se selecciona de: -O- y -NH-; Z se selecciona de: alcoxi C₁₋₆, amino, alquilamino C₁₋₆, ciano, dialquilamino C₂₋₆, hidroxilo y fenilo; R²ᵃ es H o se selecciona de: alcoxi C₁₋₆, alquilo C₁₋₆, cicloalquilo C₃₋₇ y heterociclilo; cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados de: alcoxi C₁₋₆, alquilamino C₁₋₆, alquilo C₁₋₆, alquilenhidroxilo C₁₋₆, amino, cicloalquilo C₃₋₇, ciano, dialquilamino C₂₋₈, heterociclilo opcionalmente sustituido con un grupo oxo, halógeno, hidroxilo y oxo; y R²ᵇ es H o alquilo C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595133P | 2017-12-06 | 2017-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114156A1 true AR114156A1 (es) | 2020-07-29 |
Family
ID=64744985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103577A AR114156A1 (es) | 2017-12-06 | 2018-12-06 | MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11339172B2 (es) |
| EP (1) | EP3720858B1 (es) |
| JP (1) | JP7357617B2 (es) |
| CN (1) | CN111699189B (es) |
| AR (1) | AR114156A1 (es) |
| ES (1) | ES2953576T3 (es) |
| MA (1) | MA51015A (es) |
| TW (1) | TWI822713B (es) |
| WO (1) | WO2019113359A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| TWI822713B (zh) | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| RS67259B1 (sr) | 2019-09-19 | 2025-10-31 | Novo Nordisk Healthcare Ag | Kompozicije koje aktiviraju piruvat kinazu r (pkr) |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CA3228434A1 (en) * | 2021-08-09 | 2023-02-16 | Brandon James WALSH | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| EP4392032A1 (en) * | 2021-08-26 | 2024-07-03 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| US20240409548A1 (en) | 2021-10-06 | 2024-12-12 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| FR2755439B1 (fr) * | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
| DE60033964T2 (de) * | 1999-12-17 | 2007-11-29 | Sanofi-Aventis | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| WO2006060122A2 (en) * | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| ES2777549T3 (es) * | 2014-10-14 | 2020-08-05 | Sculpt Bv | Esculpido corporal |
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| TWI822713B (zh) | 2017-12-06 | 2023-11-21 | 美商艾尼納製藥公司 | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 |
-
2018
- 2018-12-06 TW TW107143855A patent/TWI822713B/zh active
- 2018-12-06 MA MA051015A patent/MA51015A/fr unknown
- 2018-12-06 JP JP2020530969A patent/JP7357617B2/ja active Active
- 2018-12-06 EP EP18822236.8A patent/EP3720858B1/en active Active
- 2018-12-06 ES ES18822236T patent/ES2953576T3/es active Active
- 2018-12-06 WO PCT/US2018/064316 patent/WO2019113359A1/en not_active Ceased
- 2018-12-06 US US16/769,507 patent/US11339172B2/en active Active
- 2018-12-06 CN CN201880088219.8A patent/CN111699189B/zh active Active
- 2018-12-06 AR ARP180103577A patent/AR114156A1/es unknown
-
2022
- 2022-04-22 US US17/726,807 patent/US11987588B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3720858A1 (en) | 2020-10-14 |
| EP3720858C0 (en) | 2023-06-07 |
| US20200385395A1 (en) | 2020-12-10 |
| CN111699189B (zh) | 2025-02-18 |
| ES2953576T3 (es) | 2023-11-14 |
| TWI822713B (zh) | 2023-11-21 |
| US11339172B2 (en) | 2022-05-24 |
| TW201925206A (zh) | 2019-07-01 |
| MA51015A (fr) | 2021-04-21 |
| EP3720858B1 (en) | 2023-06-07 |
| CN111699189A (zh) | 2020-09-22 |
| US20220396579A1 (en) | 2022-12-15 |
| JP7357617B2 (ja) | 2023-10-06 |
| JP2021505598A (ja) | 2021-02-18 |
| US11987588B2 (en) | 2024-05-21 |
| WO2019113359A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114156A1 (es) | MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON ESTE | |
| AR108772A1 (es) | MODULADORES DEL RECEPTOR ADRENÉRGICO b-3 ÚTILES PARA EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS RELACIONADOS CON EL MISMO | |
| NI202100027A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| CL2019001264A1 (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| CL2020002224A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil péptido | |
| BR112019009129A2 (pt) | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina | |
| AR121717A1 (es) | Inhibidores de rip1k | |
| AR109179A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| AR096339A1 (es) | Agonistas del receptor de somatostatina subtipo 4 (sstr4) | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| EA201790715A1 (ru) | Новые соединения | |
| AR111307A1 (es) | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa | |
| AR109650A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
| AR120865A1 (es) | Tieniloxazolonas y análogos utilizados en el control de enfermedades de plantas | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR117539A1 (es) | INHIBIDORES DE TGF-bR1 (ALK5) ÚTILES PARA TRATAR TRASTORNOS DE PROLIFERACIÓN CELULAR | |
| AR110791A1 (es) | Promotores de la germinación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |